Skip to main content

Advertisement

Log in

BPH-Related Voiding Dysfunction—i-Tind

  • BPH-Related Voiding Dysfunction (R Lee, Section Editor)
  • Published:
Current Bladder Dysfunction Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Benign prostatic hyperplasia (BPH) is a common condition that affects a majority of the aging male population. The majority of aging male population was afflicted with lower urinary tract symptoms (LUTS). Over the past several years, there has been an armamentarium of advances in the treatment of this condition to improve a patient’s quality of life (QoL). A new treatment that shows promising results is the i-TIND system, an implantable device.

Recent Findings

We present the most current literature on this therapy. There are ongoing trials evaluating the use of the newer second-generation i-Tind, although there are currently no functional differences from the first-generation device. The pilot study of the first-generation device was shown to improve both IPSS score and Qmax over the course of 12 months with a trend to benefit in the 24 to 36-month period. The i-Tind represents another attempt to introduce an office-based procedure for the treatment of BPH. The preliminary results seem to indicate that this device shows efficacy in improving urinary symptoms.

Summary

There is promising evidence for the use of i-Tind as an office-based treatment for BPH. An important consideration, however, will center on patient selection. There will be a cohort of men who elect to undergo this minimally invasive procedure over the gold standard TURP. However, this will not be a viable treatment option for men with particularly large prostate volumes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: •• Of major importance

  1. •• Porpiglia F, et al. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up. BJU Int. 2015;116(2):278–87 First study evaluating the intermediate follow-up of the i-TIND device.

    Article  PubMed  CAS  Google Scholar 

  2. •• Porpiglia F, et al. 3-year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. BJU Int. 2018;122(1):106–12 Offered 3-years follow-up of the durability of i-TIND device. Showed device was able to improve urinary symptoms such as Qmax as well as IPSS and QoL.

    Article  PubMed  CAS  Google Scholar 

  3. Bertolo R, Fiori C, Amparore D, Porpiglia F. Follow-up of temporary implantable nitinol device (TIND) implantation for the treatment of BPH: a systematic review. Curr Urol Rep. 2018;19(6):44.

    Article  PubMed  Google Scholar 

  4. Shulman FP, et al. PD27-03 the new MediTate® temporary implantable nitinol device (I-TIND) in the treatment of bladder outlet obstruction due to BPH: results of one arm, multi-center prospective, study. J Urol. 2017;197(4).

  5. Marcon J, Magistro G, Stief CG, Grimm T. What’s new in TIND? Eur Urol Focus. 2018;4(1):40–2.

    Article  PubMed  Google Scholar 

  6. •• Porpiglia F, et al. Second-generation of temporary implantable nitinol device (i-TIND) for the relief of lower urinary tract symptoms due to BPH: results of a prospective, multi-center study at 1 year of follow-up. BJU Int. 2018; First study published detailing the effectiveness of the second generation i-TIND device.

  7. Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018;5(1):22–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bilal Chughtai.

Ethics declarations

Conflict of Interest

Dominique Guelce declares that he has no conflict of interest.

Mitali Kini declares that she has no conflict of interest.

Dominique Thomas declares that she has no conflict of interest.

Bilal Chughtai declares that he is an investigator for Medi-Tate, Astellas, and Ipsen. He is also a speaker for Boston Scientific.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on BPH-Related Voiding Dysfunction

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guelce, D., Kini, M., Thomas, D. et al. BPH-Related Voiding Dysfunction—i-Tind. Curr Bladder Dysfunct Rep 14, 9–12 (2019). https://doi.org/10.1007/s11884-019-00502-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11884-019-00502-1

Keywords

Navigation